113 related articles for article (PubMed ID: 8765515)
1. 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer.
Chan FC; Potter GA; Barrie SE; Haynes BP; Rowlands MG; Houghton J; Jarman M
J Med Chem; 1996 Aug; 39(17):3319-23. PubMed ID: 8765515
[TBL] [Abstract][Full Text] [Related]
2. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.
Rowlands MG; Barrie SE; Chan F; Houghton J; Jarman M; McCague R; Potter GA
J Med Chem; 1995 Oct; 38(21):4191-7. PubMed ID: 7473546
[TBL] [Abstract][Full Text] [Related]
3. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
4. 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha).
Ling YZ; Li JS; Liu Y; Kato K; Klus GT; Brodie A
J Med Chem; 1997 Sep; 40(20):3297-304. PubMed ID: 9379450
[TBL] [Abstract][Full Text] [Related]
5. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
Potter GA; Barrie SE; Jarman M; Rowlands MG
J Med Chem; 1995 Jun; 38(13):2463-71. PubMed ID: 7608911
[TBL] [Abstract][Full Text] [Related]
6. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro activity of some epimeric 20 alpha-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17 alpha-hydroxylase/C17,20-lyase and 5 alpha-reductase.
Ling YZ; Li JS; Kato K; Liu Y; Wang X; Klus GT; Marat K; Nnane IP; Brodie AM
Bioorg Med Chem; 1998 Oct; 6(10):1683-93. PubMed ID: 9839000
[TBL] [Abstract][Full Text] [Related]
8. Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha).
Sergejew T; Hartmann RW
J Enzyme Inhib; 1994; 8(2):113-22. PubMed ID: 7539071
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, 17α-hydroxylase-C
Banday AH; Shameem SA; Banday JA; Ganaie BA
Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase.
Li JS; Li Y; Son C; Brodie AM
J Med Chem; 1996 Oct; 39(21):4335-9. PubMed ID: 8863811
[TBL] [Abstract][Full Text] [Related]
11. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.
Wachall BG; Hector M; Zhuang Y; Hartmann RW
Bioorg Med Chem; 1999 Sep; 7(9):1913-24. PubMed ID: 10530940
[TBL] [Abstract][Full Text] [Related]
12. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
[TBL] [Abstract][Full Text] [Related]
13. 4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase.
Li J; Li Y; Son C; Banks P; Brodie A
J Steroid Biochem Mol Biol; 1992 May; 42(3-4):313-20. PubMed ID: 1606043
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17.
Wächter GA; Hartmann RW; Sergejew T; Grün GL; Ledergerber D
J Med Chem; 1996 Feb; 39(4):834-41. PubMed ID: 8632407
[TBL] [Abstract][Full Text] [Related]
15. Novel P450(17alpha) inhibitors: 17-(2'-oxazolyl)- and 17-(2'-thiazolyl)-androstene derivatives.
Zhu N; Ling Y; Lei X; Handratta V; Brodie AM
Steroids; 2003 Sep; 68(7-8):603-11. PubMed ID: 12957665
[TBL] [Abstract][Full Text] [Related]
16. C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17alpha-hydroxylase-C17, 20-lyase: synthesis and biological evaluation.
Haidar S; Hartmann RW
Arch Pharm (Weinheim); 2002; 335(11-12):526-34. PubMed ID: 12596217
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
18. A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.
Recanatini M; Bisi A; Cavalli A; Belluti F; Gobbi S; Rampa A; Valenti P; Palzer M; Palusczak A; Hartmann RW
J Med Chem; 2001 Mar; 44(5):672-80. PubMed ID: 11262078
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as potent inhibitors of 17alpha-hydroxylase/17,20-lyase (P45017alpha) derived from rat testicular microsomes.
Owen CP; Shahid I; Lee WY; Ahmed S
Bioorg Med Chem Lett; 2010 Sep; 20(17):5345-8. PubMed ID: 20675132
[TBL] [Abstract][Full Text] [Related]
20. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
Owen CP
Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
